GYRE
Gyre Therapeutics Inc.
7.40$
+3.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +34.2% | +7.5% | +52.1% | -68.4% | +2,233.9% | -58.0% | +73.5% | +24.8% | +242.0% | +13.9% | -40.7% | -93.7% | -50.0% | -3.5% | -77.2% | +155.1% | -99.4% | – | – | -65.0% | +1,294.0% | +10.9% | -6.8% | +10.2% | |
| – | – | +204.5% | -73.3% | +142.3% | -4.9% | +56.5% | +4.7% | -7.7% | +189.0% | +24.2% | – | – | -19.7% | +13.1% | +77.2% | -98.4% | -13.9% | -2.0% | +6,176.0% | -16.3% | -37.5% | -3.3% | -16.2% | +39.4% | |
| – | +19.9% | -16.0% | +106.4% | -80.3% | +3,774.2% | -59.9% | +78.0% | +26.0% | +243.5% | +13.7% | -39.2% | -105.1% | – | – | – | – | -116.9% | – | – | -102.8% | – | +11.6% | -6.4% | +9.1% | |
| – | +99.3% | +11.9% | +25.3% | +6.5% | -10.2% | +58.9% | +18.4% | -2.0% | +60.6% | +47.5% | -48.4% | -20.9% | -86.4% | +13.1% | +93.9% | +11.2% | +67.2% | +104.2% | +20.8% | +21.9% | -74.2% | -17.4% | -12.7% | +13.9% | |
| – | – | – | – | – | – | +40.7% | -99.9% | +25.7% | -1.4% | +51.1% | +8.4% | -9.0% | -66.2% | +136.6% | -3.5% | +7.9% | +23.6% | +8.6% | +20.6% | +16.3% | -7.7% | -15.6% | +9.9% | +29.1% | |
| – | +120.4% | -5.5% | +28.3% | +9.7% | -10.3% | +55.1% | +11.4% | +36.3% | +9.1% | +48.6% | -40.6% | -18.4% | -83.0% | +80.0% | +33.9% | +8.9% | +49.2% | +68.9% | +21.0% | +20.6% | +5.9% | +99.4% | -51.3% | +16.3% | |
| – | – | – | – | – | – | – | – | – | – | -174.3% | – | – | – | – | – | – | – | – | – | – | – | -830.5% | – | -29.2% | |
| – | – | – | – | +69.5% | -62.6% | +64.0% | +82.0% | -13.5% | -29.5% | -13.7% | -34.8% | -38.4% | -56.6% | +6,326.1% | – | – | – | – | – | – | +224.5% | – | – | – | |
| – | – | – | – | – | – | -1,439.0% | – | – | – | -159.1% | – | – | – | – | – | – | – | – | – | – | – | -917.7% | – | -37.8% | |
| – | +188.6% | -8.0% | -101.9% | – | – | – | – | – | – | -170.3% | – | – | +49,671.4% | -85.1% | +495.4% | -105.6% | – | -160.8% | – | – | – | +67.0% | -37.5% | -14.4% | |
| – | – | – | – | – | – | -1,439.0% | – | – | – | -178.3% | – | – | – | – | – | – | – | – | – | – | – | -4,137.1% | – | -58.4% | |
| – | – | – | – | – | – | -7,497.5% | – | – | – | -148.1% | – | – | – | – | – | – | – | – | – | – | – | +92.8% | -12.3% | -4.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.